Tocilizumab for Advanced Non-Small-Cell Lung Cancer With Concomitant Cachexia: An Observational Study

Area of Science:

• Oncology
• Immunology
• Clinical Medicine

Background:

• Cancer cachexia is a major cause of mortality in non-small-cell lung cancer (NSCLC).
• Interleukin-6 (IL-6) mediated inflammatory pathways are key drivers of cancer cachexia.
• Effective interventions for NSCLC-associated cachexia remain a significant unmet medical need.

Purpose of the Study:

• To evaluate the efficacy of tocilizumab in managing NSCLC patients with IL-6-elevated cachexia.
• To assess tocilizumab's impact on overall survival (OS) and clinical parameters in this patient cohort.

Main Methods:

• Retrospective study of 49 NSCLC patients with IL-6-elevated cachexia.
• Comparison between tocilizumab plus antitumour therapy versus antitumour therapy alone.
• Primary endpoints: OS and modified Glasgow Prognostic Score (mGPS) at 12 weeks; secondary endpoints: body weight, albumin, C-reactive protein (CRP) changes.

Main Results:

• Tocilizumab group showed significantly longer median OS (15.1 vs. 3.2 months) and higher mGPS improvement rates at 12 weeks.
• Significant improvements in body weight, albumin, CRP, and mGPS were observed in the tocilizumab group.
• Tocilizumab treatment led to better patient-reported appetite and fatigue, with a lower incidence of severe adverse events compared to the control group.

Conclusions:

• Tocilizumab offers significant survival and clinical benefits for NSCLC patients with IL-6-elevated cachexia.
• The drug improved key biomarkers, nutritional status, and symptom burden.
• Tocilizumab represents a potential therapeutic option for addressing the unmet need in cancer cachexia management.